| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Outline of Final Research Achievements |
We screened for CAP1 mutations on 200 initial presentation cases and 30 relapsed cases with acute myeloid leukemia (AML). In initial presentation subject samples, mutations were observed in one case (missense mutation), and in relapsed subject samples, mutations were observed in 3 cases (Nonsence mutation 1case, micro-insertion 2cases).We analyzed a function of the CAP1 mutation in vitro. In wild type, localization varied from cytoplasm to mitochondria by apoptotic instruction, but mutant type did not move from cytoplasm. It was found that wild/mutant type(1:1) did not induce the apoptosis that was lower than half as compared with wild type. Also mutant type did not induce the apoptosis that was lower than 1/5 as compared with wild type.
|
